10-Q: Viking Therapeutics Reports Strong Q1 2024 Results Driven by Successful Capital Raise and Positive Clinical Trial Data

Viking Therapeutics' strategic financial maneuvers and promising clinical developments in metabolic disorder treatments position the company for a robust 2024.

Summary

• Viking Therapeutics, a clinical-stage biopharmaceutical company, reported its financial results for the first quarter of 2024, highlighting significant advancements in its clinical programs and a strengthened financial position.
• The company successfully completed a public offering in March 2024, raising $597.1 million in net proceeds.
• As of March 31, 2024, Viking Therapeutics held $963.0 million in cash, cash equivalents, and short-term investments.
• Viking Therapeutics reported positive results from the Phase 2 VENTURE trial of VK2735 in patients with obesity and the Phase 1 trial of an oral formulation of VK2735.
• The company is also advancing VK2809, its lead drug candidate for NASH, with results from the Phase 2b VOYAGE study expected in the first half of 2024.
• Research and development expenses for Q1 2024 were $24.1 million, up from $11.0 million in Q1 2023, primarily due to increased clinical trial and manufacturing activities.
• General and administrative expenses for Q1 2024 were $9.97 million, compared to $9.5 million in Q1 2023.
• The net loss for Q1 2024 was $27.4 million, or $0.26 per share, compared to a net loss of $19.5 million, or $0.25 per share, in Q1 2023.

Sentiment

Score: 9

Explanation: The document reflects a highly positive sentiment due to the successful capital raise, positive clinical trial results, and strong cash position, indicating robust growth potential and investor confidence.

Positives

• Strong cash position of $963.0 million, providing financial stability for ongoing and future clinical trials.
• Successful completion of a $597.1 million public offering, demonstrating investor confidence.
• Positive Phase 2 VENTURE trial results for VK2735 in obesity, showing significant weight loss in patients.
• Encouraging Phase 1 results for the oral formulation of VK2735, paving the way for a Phase 2 trial in obesity.
• Phase 2b VOYAGE study of VK2809 for NASH successfully achieved its primary endpoint.
• Advancement of multiple clinical programs, including VK2809, VK2735, and VK0214, showcasing a diverse pipeline.
• Orphan drug designation received from the FDA for VK0214 for the treatment of X-ALD.

Negatives

• Net loss for Q1 2024 increased to $27.4 million from $19.5 million in Q1 2023.
• Research and development expenses increased significantly in Q1 2024 compared to the same period in 2023.
• The company has a limited operating history and has yet to generate any revenue from product sales.
• The company is dependent on the success of its drug candidates, which face regulatory and commercialization risks.

Risks

• The company is expected to incur significant operating losses in the future.
• The company is substantially dependent on technologies licensed from Ligand Pharmaceuticals Incorporated.
• Clinical trials may produce unfavorable results or experience delays, impacting development timelines and costs.
• The company relies on third parties to conduct preclinical studies and clinical trials.
• Competitors may develop and market drugs that are approved faster, better tolerated, have a more favorable safety profile, or are more effective.
• Unstable market and economic conditions may adversely affect the company's business and financial condition.
• The company may not be successful in obtaining or maintaining necessary rights to its drug candidates.
• The company may need to raise additional capital, which may be unavailable or cause dilution.
• The company's drug candidates may cause undesirable side effects.
• The company is subject to extensive regulation, which can be costly and time-consuming.
• The company faces manufacturing risks and relies on third-party manufacturers.
• The company may not be able to protect its intellectual property rights.
• The company may be subject to claims of intellectual property infringement.
• The company may be unable to attract and retain key personnel.
• The company is exposed to product liability risks.
• The company is subject to fraud and abuse and similar laws and regulations.
• The company is subject to global privacy and data security requirements.
• The company is subject to certain U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and regulations.
• The company's stock price may be highly volatile.
• The company's management owns a significant percentage of the company's stock and can exert significant control over matters subject to stockholder approval.
• The company is subject to risks related to its status as a public company.
• Sales of a substantial number of shares of the company's common stock in the public market by existing stockholders or future issuances of common stock or rights to purchase common stock could cause the company's stock price to fall.
• The company is at risk of securities class action litigation.
• The company's ability to use its net operating loss carryforwards may be subject to certain limitations.
• Provisions in the company's charter documents and Delaware law could make it more difficult or expensive for a third party to acquire the company or change the board of directors or current management.
• The company's bylaws designate the Court of Chancery of the State of Delaware as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by stockholders.
• Investors' expectations of the company's performance relating to environmental, social and governance factors may impose additional costs and expose the company to new risks.

Future Outlook

The company plans to initiate a Phase 2 trial with the oral formulation of VK2735 in obesity later in 2024 and expects results from the Phase 2b VOYAGE study of VK2809 in the first half of 2024 and results from the Phase 1b study of VK0214 mid-year in 2024.

Industry Context

Viking Therapeutics is developing treatments for metabolic and endocrine disorders, a growing area of focus in the biopharmaceutical industry. The company's lead candidates, VK2809 for NASH and VK2735 for obesity, target large and expanding markets with significant unmet medical need. The positive clinical data for VK2735 positions Viking Therapeutics as a potential competitor in the rapidly growing obesity market, currently dominated by Novo Nordisk and Eli Lilly.

Comparison to Industry Standards

• VK2735's weight loss results in the Phase 2 VENTURE trial are comparable to those observed in trials of other GLP-1 and GIP receptor agonists, such as semaglutide (Wegovy) from Novo Nordisk A/S, and tirzepatide (Zepbound) from Eli Lilly and Company.
• VK2809's results in the Phase 2b VOYAGE study are compared to those of resmetirom (Rezdiffra) from Madrigal Pharmaceuticals, Inc., which is the only therapy currently approved in the U.S. for the treatment of NASH.
• Other companies developing treatments for NASH include Galmed Pharmaceuticals Ltd., Galectin Therapeutics Inc., Inventiva S.A., Novo Nordisk A/S, Akero Therapeutics, Inc., Gilead Sciences, Inc., Eli Lilly and Company, Pfizer Inc., 89bio, Inc., Sagimet Biosciences Inc., Hanmi Pharmaceutical Co., Ltd., Boehringer Ingelheim International GmbH, Ionis Pharmaceuticals, Inc., Hepion Pharmaceuticals, Inc., HighTide Therapeutics Inc., GlaxoSmithKline plc., Alnylam Pharmaceuticals, Inc./ Regeneron Pharmaceuticals Inc., Merck & Co., Inc., and Altimmune, Inc.
• Other companies developing treatments for obesity include Altimmune, Inc., Amgen Inc., AstraZeneca, BioAge Labs, Inc., Biophytis SA, D&D Pharmatech, Inc., ERX Pharmaceuticals Inc., F. Hoffmann-La Roche Ltd, Hanmi Pharmaceutical Co., Ltd., Kallyope Inc., Pfizer Inc., Regeneron Pharmaceuticals Inc., Rivus Pharmaceuticals Inc., Scholar Rock, Inc., Structure Therapeutics Inc., Terns Pharmaceuticals, Inc., Ventyx Biosciences, Inc., and Zealand Pharma A/S.

Legal Proceedings

• In December 2022, Viking Therapeutics filed suit against Ascletis Bioscience Co., Ltd., Gannex Pharma Co., Ltd., Ascletis Pharmaceuticals Co., Ltd., Ascletis Pharma Inc., and Jinzi Jason Wu in the Southern District of California, San Diego division, alleging: (1) violation of the Defend Trade Secrets Act; (2) violation of the California Uniform Trade Secrets Act; (3) breach of contract; (4) breach of the implied covenant of good faith and fair dealing; and (5) tortious interference with contract.
• In a related action, Viking Therapeutics also filed suit against the same defendants in the International Trade Commission for unlawful and unfair methods of competition.

Stakeholder Impact

• Positive clinical trial results and a strong financial position could positively impact shareholders by increasing the company's value and potential for future growth.
• Employees may benefit from the company's growth and potential for success, although there are risks associated with the company's reliance on key personnel.
• Patients with NASH, obesity, and X-ALD could benefit from the development of new and effective treatments.
• Suppliers and creditors may be impacted by the company's financial performance and ability to meet its obligations.

Next Steps

• The company plans to initiate a Phase 2 trial with the oral formulation of VK2735 in obesity later in 2024.
• Results from the Phase 2b VOYAGE study of VK2809 are expected in the first half of 2024.
• Results from the Phase 1b study of VK0214 are expected mid-year in 2024.

Key Dates

Keywords

metabolic disorders, endocrine disorders, NASH, obesity, X-ALD, thyroid hormone receptor beta agonist, GLP-1 receptor agonist, GIP receptor agonist, clinical trials, biopharmaceutical, drug development, VK2809, VK2735, VK0214, VOYAGE study, VENTURE study, FDA approval, capital raise, public offering